CORT News

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated to Secure Counsel Before Important Deadline in Securities Class Action - CORT

Robbins LLP Urges Stockholders Who Lost Money Investing in CORT to Contact The Firm For Information About Recovering Their Losses From Corcept Therapeutics Inc.

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

Pomerantz LLP Advises of Securities Class Action Involving Corcept Therapeutics Incorporated – CORT

Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately

Class Action Filed Against Corcept Therapeutics Incorporated (CORT) Seeking Recovery for Investors – Contact Levi & Korsinsky

ROSEN, A LEADING AND RANKED FIRM, Encourages Corcept Therapeutics Incorporated to Secure Counsel Before Important Deadline in Securities Class Action – CORT

Deadline Approaching: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline